RU94045251A - Антипролиферативные хиназолины, способы получения, фармацевтическая композиция, способ лечения - Google Patents

Антипролиферативные хиназолины, способы получения, фармацевтическая композиция, способ лечения

Info

Publication number
RU94045251A
RU94045251A RU94045251/04A RU94045251A RU94045251A RU 94045251 A RU94045251 A RU 94045251A RU 94045251/04 A RU94045251/04 A RU 94045251/04A RU 94045251 A RU94045251 A RU 94045251A RU 94045251 A RU94045251 A RU 94045251A
Authority
RU
Russia
Prior art keywords
compounds
synthesis
methods
antiproliferative
quinazolines
Prior art date
Application number
RU94045251/04A
Other languages
English (en)
Other versions
RU2135481C1 (ru
Inventor
Э.Веббер Стефен
Us]
М.Блекман Тед
Эттард Джон
Р.Джонс Теренс
Д.Варни Майкл
Original Assignee
Агурон Фармасьютикалз
Агурон Фармасьютикалз, Инк.
Инк. (US)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Агурон Фармасьютикалз, Агурон Фармасьютикалз, Инк., Инк. (US) filed Critical Агурон Фармасьютикалз
Publication of RU94045251A publication Critical patent/RU94045251A/ru
Application granted granted Critical
Publication of RU2135481C1 publication Critical patent/RU2135481C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Рассмотрены хиназолиновые соединения, обладающие антипролиферативным действием, таким как противоопухолевая активность, способы получения этих соединений, фармкомпозиции, содержащие их, и использование этих соединений. Эти соединения ингибируют пролиферацию клеток высших организмов и микроорганизмов, таких как бактерии, дрожжи и грибы. Предпочтительные хиназолиновые соединения способны ингибировать ферментативную тимидилатсинтазу. Ингибирование ферментативной тимидилатсинтазы включает действие, определенное выше.

Claims (1)

  1. Рассмотрены хиназолиновые соединения, обладающие антипролиферативным действием, таким как противоопухолевая активность, способы получения этих соединений, фармкомпозиции, содержащие их, и использование этих соединений. Эти соединения ингибируют пролиферацию клеток высших организмов и микроорганизмов, таких как бактерии, дрожжи и грибы. Предпочтительные хиназолиновые соединения способны ингибировать ферментативную тимидилатсинтазу. Ингибирование ферментативной тимидилатсинтазы включает действие, определенное выше.
RU94045251A 1992-03-31 1993-03-26 Хиназолиновые соединения или их фармацевтически приемлемые соли и фармацевтическая композиция RU2135481C1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/861,030 US5430148A (en) 1992-03-31 1992-03-31 Antiproliferative quinazolines
US07/861.030 1992-03-31
US07/861,030 1992-03-31
PCT/US1993/002636 WO1993020055A1 (en) 1992-03-31 1993-03-26 Antiproliferative quinazolines

Publications (2)

Publication Number Publication Date
RU94045251A true RU94045251A (ru) 1996-07-20
RU2135481C1 RU2135481C1 (ru) 1999-08-27

Family

ID=25334675

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94045251A RU2135481C1 (ru) 1992-03-31 1993-03-26 Хиназолиновые соединения или их фармацевтически приемлемые соли и фармацевтическая композиция

Country Status (20)

Country Link
US (3) US5430148A (ru)
EP (1) EP0637300B1 (ru)
JP (1) JP3272357B2 (ru)
KR (1) KR100226114B1 (ru)
AT (1) ATE205197T1 (ru)
AU (1) AU681075B2 (ru)
CA (2) CA2132514C (ru)
DE (1) DE69330715T2 (ru)
DK (1) DK0637300T3 (ru)
ES (1) ES2162818T3 (ru)
FI (1) FI113765B (ru)
HU (1) HU222523B1 (ru)
MD (1) MD1638G2 (ru)
NO (1) NO307829B1 (ru)
NZ (1) NZ251804A (ru)
PT (1) PT637300E (ru)
RU (1) RU2135481C1 (ru)
SG (2) SG46672A1 (ru)
TJ (1) TJ272B (ru)
WO (1) WO1993020055A1 (ru)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5430148A (en) * 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
US5593999A (en) * 1995-06-07 1997-01-14 Nair; Madhavan G. Non-classical folate analogue inhibitors of glycinamide ribonucleotide formyltransferase (GARFT)
US5783577A (en) * 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
WO1997042192A1 (de) * 1996-05-07 1997-11-13 Basf Aktiengesellschaft Imidazo-chinazoline, sie enthaltende mittel und deren verwendung zur bekämpfung von schadpilzen und tierischen schädlingen
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
CN1307421C (zh) * 1997-08-08 2007-03-28 塞米得肿瘤学美国公司 克服生物及化学治疗抗性的方法与组合物
DE69900841T2 (de) 1998-01-23 2002-10-02 Newbiotics Inc Durch enzymkatalyse erhaltene therapeutische substanzen.
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6706721B1 (en) * 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CN1391486A (zh) 1999-07-22 2003-01-15 新生物公司 治疗对治疗有抗性的肿瘤的方法
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7087613B2 (en) * 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (ru) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стойкий полиморф гидрохлорида n-(3-этинилфенил)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина, способ его получения (варианты) и фармацевтическое применение
BR0114713A (pt) * 2000-10-16 2004-01-13 Neopharm Inc Formulação lipossÈmica de mitoxantrona
US6486199B1 (en) 2001-06-21 2002-11-26 Medicines For Malaria Venture Mmv International Centre Cointrin Spiro and dispiro 1,2,4-trioxolane antimalarials
WO2003043995A1 (en) * 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
AU2003213092A1 (en) * 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
CA2485148A1 (en) * 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
WO2003103575A2 (en) * 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
EP1556357A4 (en) * 2002-06-14 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
US7371778B2 (en) * 2002-06-21 2008-05-13 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US6906205B2 (en) * 2002-06-21 2005-06-14 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US20080125441A1 (en) * 2002-06-21 2008-05-29 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US7211580B2 (en) * 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
AU2003262747A1 (en) * 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
US7557115B2 (en) * 2002-09-30 2009-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
EP1682534A2 (en) * 2003-11-03 2006-07-26 Cytokinetics, Inc. Pyrimidin-4-one compounds, compositions, and methods
WO2005046588A2 (en) * 2003-11-07 2005-05-26 Cytokinetics, Inc. Compounds, compositions, and methods
JP2007513154A (ja) * 2003-12-08 2007-05-24 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
CA2591948C (en) * 2005-01-19 2013-11-12 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8067620B2 (en) * 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
CN1303080C (zh) * 2005-07-18 2007-03-07 康辰医药发展有限公司 盐酸洛拉曲克的合成工艺
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
CN101353343B (zh) * 2007-07-27 2012-07-04 上海医药工业研究院 高纯度盐酸诺拉曲塞二水合物的制备方法
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
JP5756096B2 (ja) * 2009-06-12 2015-07-29 ソックプラ−シアンセ エ ジェニー エス．ウ．セ． グアニンリボスイッチ結合化合物及び抗生物質としてのその使用
PL2513115T3 (pl) 2009-12-18 2014-04-30 Basilea Pharmaceutica Ag Antybiotyki tricykliczne
EP2721034B1 (en) 2011-06-17 2016-07-20 Basilea Pharmaceutica AG N-heterotricyclic antibiotics
RU2507198C1 (ru) * 2012-09-10 2014-02-20 Владимир Иванович Петров Производные хиназолина, обладающие ноотропной и антигипоксической активностью
RU2507199C1 (ru) * 2012-09-10 2014-02-20 Владимир Иванович Петров Производные хиназолина, обладающие антидепрессивной, анксиолитической и ноотропной активностью
RU2622638C1 (ru) * 2016-07-14 2017-06-19 Владимир Иванович Петров Производные хиназолин-4(3н)-она, обладающие нейро- и кардиопротекторной активностью
SG11202108333YA (en) 2019-02-14 2021-08-30 Som Innovation Biotech S A Triamterene or nolatrexed for use in the treatment of phenylketonuria

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1817982A (en) * 1931-08-11 Winfrid hentrich and max habdtmann
CA793845A (en) * 1968-09-03 Davoll John Amine compounds and production thereof
GB206565A (en) * 1922-08-03 1923-11-05 Walter Wood Tullis Improvements in or relating to the concentration and preparation for smelting of iron ores
GB1045180A (en) * 1963-09-20 1966-10-12 Parke Davis & Co Quinazoline derivatives
GB1212613A (en) * 1967-02-28 1970-11-18 Chinoin Gyogyszer Es Vegyeszet 4-quinazolone derivatives and process for the preparation thereof
GB1161644A (en) * 1967-09-11 1969-08-13 Parke Davis & Co Quinazoline Compounds and process means for producing the same
US4048312A (en) * 1973-10-30 1977-09-13 Eli Lilly And Company 2,4-Diaminoquinazolines as antithrombotic agents
IT1050750B (it) * 1975-12-05 1981-03-20 Erba Carlo Spa Derivati della 3.4 di idro chinazolina
US4223143A (en) * 1978-12-11 1980-09-16 Siegfried Aktiengesellschaft Quinazoline derivatives
US4391809A (en) * 1979-10-15 1983-07-05 Warner-Lambert Company Methods for treating psoriasis
DE3069468D1 (en) * 1979-12-19 1984-11-22 Nat Res Dev Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
US4853221A (en) * 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
JPS57156467A (en) * 1981-03-20 1982-09-27 Asahi Chem Ind Co Ltd 2,4-disubstituted-6-quinazolinesulfonamide derivative
JPS6136273A (ja) * 1984-07-26 1986-02-20 Mitsubishi Yuka Yakuhin Kk ２−フエニルアルキル−４（３ｈ）−キナゾリノン誘導体
US4749698A (en) * 1985-07-08 1988-06-07 Rorer Pharmaceutical Corporation Antihypertensive derivatives
GB8513754D0 (en) * 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
GB8707053D0 (en) * 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4857530A (en) * 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
GB8809978D0 (en) * 1988-04-27 1988-06-02 Ici Plc Anti-tumour agents
EP0365763A1 (en) * 1988-09-30 1990-05-02 Agouron Pharmaceuticals, Inc. Antiproliferative cyclic compounds
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
NO171069C (no) * 1990-05-29 1993-01-20 Protan Biopolymer As Kovalent tverrbundne, sterkt svellende alkalimetall- og ammonium-alginatgeler, samt fremgangsmaate for fremstilling derav
ZA913730B (en) * 1990-05-30 1992-02-26 Ici Plc Anti-tumor compounds
US5430148A (en) * 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines

Also Published As

Publication number Publication date
KR100226114B1 (ko) 1999-10-15
NZ251804A (en) 1997-06-24
HU9402799D0 (en) 1994-12-28
TJ272B (en) 2000-10-05
AU681075B2 (en) 1997-08-21
CA2474211A1 (en) 1993-10-14
US5885996A (en) 1999-03-23
MD1638F2 (en) 2001-03-31
JPH07505395A (ja) 1995-06-15
FI113765B (fi) 2004-06-15
EP0637300A1 (en) 1995-02-08
RU2135481C1 (ru) 1999-08-27
HUT68580A (en) 1995-06-28
DK0637300T3 (da) 2001-12-10
DE69330715D1 (de) 2001-10-11
SG93183A1 (en) 2002-12-17
CA2474211C (en) 2006-10-03
CA2132514C (en) 2004-10-26
WO1993020055A1 (en) 1993-10-14
HU222523B1 (hu) 2003-08-28
ATE205197T1 (de) 2001-09-15
JP3272357B2 (ja) 2002-04-08
US5707992A (en) 1998-01-13
DE69330715T2 (de) 2002-02-14
MD1638G2 (ru) 2001-09-30
US5430148A (en) 1995-07-04
ES2162818T3 (es) 2002-01-16
SG46672A1 (en) 1998-02-20
FI944525A (fi) 1994-09-29
NO307829B1 (no) 2000-06-05
FI944525A0 (fi) 1994-09-29
AU3966493A (en) 1993-11-08
CA2132514A1 (en) 1993-10-14
PT637300E (pt) 2002-01-30
EP0637300B1 (en) 2001-09-05
NO943629L (no) 1994-09-29
NO943629D0 (no) 1994-09-29

Similar Documents

Publication Publication Date Title
RU94045251A (ru) Антипролиферативные хиназолины, способы получения, фармацевтическая композиция, способ лечения
FI915810A0 (fi) Foerfarande foer doedande av celler utan soenderdelning av cellerna.
Seki et al. Antitumor activity of rice‐shochu post‐distillation slurry and vinegar produced from the post‐distillation slurry via oral administration in a mouse model
WO2004009112A8 (en) Use of urease for inhibiting cancer cell growth
Romano et al. Utilization of amino acids as carbon sources by Streptomyces fradiae
Islam et al. Inhibition of some fungal pathogens of host phylloplane by Bacillus megaterium/Hemmung einiger pilzlicher Krankheitserreger in der Phyllosphäre von Wirtspflanzen durch Bacillus megaterium
AU2267899A (en) Fungi of the genus piriformospora
Banerjee et al. Radiomimetic property of furazolidone and the caffeine enhancement of its lethal action on the vibrios
Hou et al. Microbial Transformations of Peptide Antibiotics: V. PURIFICATION AND PROPERTIES OF THE ACTINOMYCIN LACTONASE FROM ACTINOPLANES MISSOURIENSIS
Pruess et al. ANTIMETABOLITES PRODUCED BY MICROORGANISMS. XI. 1) 1-(S)-HYDROXY-2-(S, S)-VALYLAMIDO-CYCLOBUTANE-1-ACETIC ACID
GR3027661T3 (en) Treatment of tumors with neurotrophic factors and cell proliferation inhibitors.
May et al. A rapid method for extraction of membrane-plate grown fungal cultures
Greaves et al. The degradation of nucleic acids by Cytophaga johnsonii
JPS6057833B2 (ja) Ｌ−トリプトフアンの製造方法
JPS6474987A (en) Novel proline acylase and its production
Chandra Effect of 5-fluorouracil on the gibberellic acid-induced formation of thermolabile α-amylase molecules in barley aleurone cells
KR930011713B1 (ko) 미생물을 이용한 계분 및 인분 정화제
Binkley Some biochemical changes in penicillin-inhibited Escherichia coli cells
YU154091A (sh) Antiproliferativna supstituisana naftalenska jedinjenja
SU566874A1 (ru) Питательна среда дл вы влени клетчаткоразрушающих микроорганизмав
RU94045291A (ru) Соединения полезные при лечения аллергических и воспалительных заболеваний, композиция, способ лечения
JPS55102393A (en) Enzymatic preparation of tyramine
RU2026882C1 (ru) Способ культивирования coprinus cinereus
Monib et al. Suitable media for isolation of yeasts from Egyptian soils
Khalaf Isolation and Identification of two bioactive compounds from basidiomycetes fungus Coprinus sp.

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090327